The role of bone biopsy in clinical practice and research  by Malluche, Hartmut H. et al.
Kidney International, Vol. 56, Suppl. 73 (1999), pp. S-20–S-25
The role of bone biopsy in clinical practice and research
HARTMUT H. MALLUCHE, M. CHRIS LANGUB, and MARIE-CLAUDE MONIER-FAUGERE
Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky,
Lexington, Kentucky, USA
The role of bone biopsy in clinical practice and research. Sur- vides information on the type of renal osteodystrophy,
vival rates of patients on dialysis have increased with improved the degree of severity of the lesions, and the presence
dialytic therapy. However, the resultant increased duration of and amount of aluminum deposition in bone [1].dialysis has led to a rise in renal osteodystrophy (ROD). Be-
Bone biopsies have been used for research purposescause this metabolic bone disease can produce fractures, bone
to assess the effects of new therapies on bone. Morepain, and deformities late in the course of the disease, preven-
tion and early treatment are essential. Types of ROD include recently, the methods of in situ hybridization histochem-
predominant hyperparathyroid bone disease, low turnover istry and immunohistochemistry are providing the means
bone disease (including osteomalacia and adynamic bone dis-
to study local biomolecules that play a role in bone me-ease), and mixed uremic osteodystrophy. Serum PTH levels
tabolism.are commonly used to assess bone turnover in dialyzed patients.
However, a recent study in our laboratory found that serum This article discusses the types and evolution of renal
PTH levels between 65 and 450 pg/ml seen in the majority osteodystrophy, presents an overview of bone biopsy
of dialysis patients are not predictive of the underlying bone techniques, discusses clinical applications of bone biopsy,disease. To date, bone biopsy is the most powerful and informa-
and reviews the research implications of in situ hybridiza-tive diagnostic tool to provide important information on pre-
tion histochemistry and immunohistochemistry.cisely the type of renal osteodystrophy affecting patients, the
degree of severity of the lesions, and the presence and amount
of aluminum deposition in bone. Bone biopsy is not only useful
in clinical settings but also in research to assess the effects of TYPES OF RENAL OSTEODYSTROPHY
new therapies on bone. The methods of in situ hybridization Despite a mostly common initial pathogenetic path-histochemistry (ISHH) and immunohistochemistry (IHC) are
way, renal osteodystrophy is not a uniform bone disease.providing the means to study local biomolecules that play a
role in bone metabolism. As these research tools become more The forms of renal osteodystrophy consist of predomi-
refined, they will become increasingly valuable in the study of nant hyperparathyroid bone disease, low turnover bone
bone. Alternatives to the bone biopsy continue to be pursued, disease, including osteomalacia and adynamic bone dis-
but they have not been proven to have the same specificity or
ease, and mixed uremic osteodystrophy. Transformationsensitivity to effectively determine the potential value of a
from one form to another can occur [2].specific therapeutic regimen.
Predominant hyperparathyroid bone disease
Predominant hyperparathyroid bone disease (PHBD)Renal failure produces changes in mineral metabolism
that affect bone structure, turnover, and cellular charac- is characterized by a marked increase in bone turnover.
teristics. When patients reach end-stage renal failure and Irregularly shaped trabecules display numerous abnor-
require chronic maintenance dialysis, nearly all of them mal remodeling sites (Fig. 1), and an unusually high num-
have abnormal bone histology. Improved dialytic ther- ber of bone cells are irregular in arrangement and shape.
apy has increased survival rates of patients on dialysis, Deep, irregular resorption cavities often dissect or tunnel
but the resultant increased duration of dialysis has led the trabecules. Numerous enlarged osteoclasts contain
to a rise in renal osteodystrophy, a metabolic bone dis- multiple nuclei with prominent nucleoli. Osteoblast shape
ease that can produce fractures, bone pain, and deformi- changes from cuboidal to polygonal or spindle shaped.
ties late in the course of the disease. Therefore, preven- The usual palisade-like monolayer of osteoblasts can be
tion of renal osteodystrophy is critical. To date, bone replaced by atypical multilayered arrangements of cells
biopsy is the most informative diagnostic tool and pro- with variable orientation toward the bone surface (from
parallel to perpendicular). Osteoid surface and volume
increase, and an osteoid seam can thicken because ofKey words: bone biopsy, mineralized bone histology, renal osteodys-
trophy. collagen overproduction. The resulting osteoid is primar-
ily of the woven, irregular type. In advanced cases, fibro- 1999 by the International Society of Nephrology
S-20
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Fig. 1. Predominant hyperparathyroid bone disease. High fraction of
Fig. 2. Low-turnover osteomalacia. Increase in osteoid volume. Widetrabecular surface covered by osteoid seams. High osteoid–osteoblast
osteoid seams. Absence of osteoblasts and resorption surface. Unde-interface. High bone–osteoclast interface with appearance of deep re-
calcified, 3 mm thick section of human iliac bone (modified Masson-sorption lacuna. Marrow fibrosis. Undecalcified, 3 mm thick section of
Goldner stain, 3200 magnification).human iliac bone (modified Masson-Goldner stain, 3125 magnification).
Usually, only a few thin single labels of tetracycline aresis replaces bone marrow entirely, reflecting the irregular
observed. Other characteristics include predominantlyactivity of osteoblasts in which the regular activity of
lamellar bone structure, few active bone formation sites,individual cells is decreased. Numerous irregular osteo-
and markedly reduced mineralizing surfaces.cytic lacunae within woven osteoid and mineralized bone
This type has two subgroups: osteomalacia (LTOM)result from the increased number of osteoblasts en-
and adynamic renal bone disease (ABD). LTOM is char-trapped in bone, and the mineral apposition rate and
acterized by an accumulation of unmineralized matrixthe extent and number of mineralizing sites are notably
in which a diminution in mineralization precedes or isincreased. Findings of thick osteoid seams and diffuse,
more pronounced than the inhibition of collagen deposi-
irregular tetracycline uptake in woven bone are some-
tion (Fig. 2). In LTOM, unmineralized bone makes up a
times mistakenly diagnosed as osteomalacia. sizable portion of trabecular bone volume. The increased
A marked increase in bone turnover often leads to lamellar osteoid volume results from the presence of
cancellization of the cortical bone. This causes a net wide osteoid seams that cover much of the trabecular
decrease in cortical bone volume most evident in the surface. The occasional presence of woven bone buried
appendicular skeleton. PHBD usually presents with high within the trabeculae indicates past high bone turnover.
bone volume, but malnutrition, immobilization, or other Osteoclasts, when present, are usually seen within tra-
causes can markedly reduce bone volume. Also, areas becular bone or at the small fraction of trabecular surface
of high bone mass may be adjacent to pseudocysts con- left without osteoid coating. With ABD, bone volume
sisting primarily of hyperplastic or fibrotic bone marrow. is frequently reduced. Reduced mineralization is coupled
In any case, bone strength cannot be equated with high with a parallel decrease in bone formation. ABD is char-
bone volume in PHBD patients because the irregular acterized by few osteoid seams (Fig. 3).
trabeculae may lose their proper three-dimensional ar-
chitecture and connectivity. Also, the poorly mineralized Mixed uremic osteodystrophy
trabeculae consist mainly of mechanically deficient wo- Mixed uremic osteodystrophy (MUO) is caused pri-
ven bone with a propensity to fracture. This disease marily by defective mineralization with or without in-
creates a particularly fragile, fracture-prone bone; thus, creased bone formation and by increased parathyroid
the use of the term “osteosclerosis” is inappropriate. hormone activity on bone, features that may coexist in
varying degrees in different patients. Bone volume/tissue
Low turnover bone disease volume is extremely variable and depends on a dominant
Representing the other end of the spectrum from pathogenic cause. Other features include increased num-
PHBD, low turnover uremic osteodystrophy is marked bers of heterogeneous remodeling sites and usually an
by a profound decrease in active remodeling sites. Cer- increase in osteoclasts. Active foci with numerous cells,
tain features reflect a marked decrease in osteoblastic peritrabecular fibrosis, and woven osteoid seams coexist
with adjacent lamellar sites with a more reduced activity.activity and there are few osteoclasts and osteoblasts.
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Fig. 3. Adynamic bone disease. No accumulation of osteoid. Absence Fig. 4. Mixed uremic osteodystrophy. Increased fraction of trabecular
surface covered by osteoid. Osteoid seams are wide or normal. Resorp-of bone formation. Absence of active bone resorption. Undecalcified,
3 mm thick section of human iliac bone (modified Masson-Goldner tion lacunae with osteoclasts. Evidence of some peritrabecular fibrosis.
Undecalcified, 3 mm thick section of human iliac bone (modified Mas-stain, 3125 magnification).
son-Goldner stain, 3125 magnification).
Therefore, greater production of lamellar or woven oste-
oid causes the accumulation of osteoid with normal or pattern of renal osteodystrophy in 2248 patients over
13 years (from 1983 to 1995), distribution of the fourincreased thickness of osteoid seams (Fig. 4). Although
active mineralizing surfaces are often present in woven histologic forms varied [3]. MUO was found in the major-
ity of patients over the years, but a slight decrease wasbone with higher mineralization rate and diffuse labeling,
mineralization surfaces may be low in lamellar bone with seen in 1990 and 1995. PHBD was observed in a large
number of patients in 1983, but decreased constantlya low mineral apposition rate.
until 1988, then increased gradually to reach a level in
Evolution of renal osteodystrophy 1995 similar to the one found in 1983. LTOM incidence
decreased progressively over the 13 years of the survey.In the past, diversity in bone lesions was partly attrib-
uted to aluminum toxicity in bone. The major sources The number of patients with ABD, which was first diag-
nosed in 1984 increased until the late 1980s, then stayedof contamination in end-stage renal disease (ESRD) pa-
tients are aluminum-containing phosphate binders and approximately the same. The trends for patients on he-
modialysis and peritoneal dialysis were similar for thehigh aluminum content of water and dialysate. High mor-
bidity and mortality accompany severe aluminum intoxi- four histologic groups. However, peritoneal dialysis pa-
tients consistently exhibited more histologic signs ofcation, and deferoxamine (DFO) chelation, though effi-
cient, is not without risks. Therefore, efforts were made ABD and fewer signs of PHBD than did hemodialysis
patients.to develop tests capable of diagnosing this disease. De-
termining serum levels of aluminum before and after Between 1983 and 1984, the number of biopsied pa-
tients positive for aluminum increased from approxi-DFO treatment, alone or in association with serum PTH,
proved useful, but only in those patients with high base- mately 40% to approximately 60%, remained stable until
1992, then tended to decrease. In 1995, however, approx-line serum aluminum levels who showed a marked in-
crease after DFO challenge and had low serum PTH imately 25% of the biopsies analyzed still showed alumi-
num in bone. Patients with low bone turnover, eitherlevels. Therefore, bone biopsies were the only unequivo-
cal means to establish aluminum accumulation in bone LTOM or ABD, showed higher aluminum deposition
than patients with other forms of renal osteodystrophy,and determine the type of renal osteodystrophy.
Today, aluminum dialysate content is under better and this did not change with time. More patients with
stainable aluminum . 30% were in the LTOM, ABD,control, and aluminum-containing phosphate binders
have largely been replaced with calcium salts. To over- and MUO groups than in the PHBD group. From 1984
to 1995, bone aluminum accumulation decreased withincome parathyroid gland overactivity, therapeutic regi-
mens ensuring better control of serum calcium and phos- each histologic group, and in 1995 aluminum accumula-
tion was mostly seen in patients with MUO and ABD.phorus levels and correction of calcitriol deficiency are
also widely used. In spite of recent strategies, however, aluminum accu-
mulation has not completely disappeared, and dialyzedIn a previous study in which we analyzed the changing
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patients still present with PHBD, MUO, and ABD. Re- vertical or superior biopsies of the anterior iliac crest
result in very small morbidity and no mortality as acent evidence shows that low bone turnover has both
histologic and clinical relevance. Patients with this abnor- result of the procedure [4]. The operator’s experience is
important in minimizing morbidity and in obtaining anmality were found to have abnormal calcium homeosta-
sis, higher incidence of fractures, more bone pain, de- adequate specimen. Use of recently developed tech-
niques should further decrease any complications. Pa-layed healing, and higher morbidity and mortality than
did patients exhibiting other histologic abnormalities. tient reports of pain range from none to moderate and
rarely severe.
BONE BIOPSY TECHNIQUES Qualitative and quantitative evaluation of bone
Prerequisites for bone biopsies: Bone labeling Qualitative and quantitative evaluations of the bone
sample constitute the final steps in processing a boneThe first prerequisite for an informative bone biopsy
is proper in vivo labeling with specific, nontoxic, time- biopsy. Qualitative assessment consists of such factors
as the suitability of a biopsy for morphometric analysis,spaced bone markers before the biopsy. Antibiotics from
the tetracycline family are used because they have spon- the amount of sample needed, where histologic struc-
tures should be measured, and what elements to evalu-taneous fluorescence and bind to actively forming bone
surfaces. With labeling, the level of bone turnover and ate. With quantitative evaluation, numerical values are
assigned to the various elements constituting bone [5].rate of bone formation can be determined, and possible
mineralization abnormalities can be identified. A double Potential differences between groups of patients or nor-
mal individuals or changes occurring after treatment canlabeling technique is best, although the schedule is some-
what more complicated for patients than one prolonged then be statistically evaluated. Compared to earlier tech-
niques for statistical evaluation, the semiautomatic com-single administration. In most cases, the first label is
administered for 2 days followed by an 8-to 15-day free puterized method introduced by Malluche et al [6]
interval. Anything fewer than 8 days lessens the distinc- greatly reduced the time required to measure surface,
tion between labels, particularly in the case of a mineral- thickness, volume, and profile count of bone. Software
ization defect. Anything more than 15 days may artifi- programs developed for use with the semiautomatic
cially increase the number of single labels because the method are all reliable for calculating areas and counts,
number of forming sites being completed or started will but some differences exist in computation of lengths,
probably increase. During the 2–4 days after the free thus affecting all parameters. Advantages to the compu-
interval, the patient takes a second course of antibiotics. terized-assisted histomorphometric analysis of bone also
Bone biopsy is then performed 4–6 days after the last include many means of data verification, and the data
administration of tetracycline. During this delay, the tet- obtained can be automatically transferred to any statisti-
racycline becomes slightly buried within mineralized os- cal software, thus avoiding entry error.
teoid and thus does not leach out. In an emergency, Fully automated image analyzers are available greatly
labeling can be shortened to a 1-day-on, 6-days-off and reducing the time required to evaluate bone slides. Al-
1-day-on schedule with a single dose of oral tetracycline though they assess parameters of bone structure, they
per day (1.0–1.5 g of tetracycline or 600–900 mg of Declo- are not yet reliable in discriminating such elements as
mycint). Gastrointestinal side effects may be greater cellular details, detecting woven vs. lamellar bone, and
with this approach. Using two labels with different colors recognizing erosion surface. However, complete auto-
assures accurate assessment of the mineralization rate. matic analysis of bone may be possible in the future,
Tetracycline hydrochloride has a light yellow and de- with improved video cameras, staining techniques, and
meclocycline hydrochloride (Declomycint) a yellow- computerized image-analysis capabilities.
orange fluorescence. With the use of only one type of
tetracycline, the two labels can merge in states of low
CLINICAL APPLICATIONSbone turnover and be unrecognizable as a double label.
Nephrologists must determine a patient’s level of boneFor patients with normal renal function, dosages of tetra-
turnover to apply the correct therapy. Serum PTH levelscycline hydrochloride and Declomycint are usually 500
measured with radioimmunometric assay are commonlymg and 300 mg t.i.d., respectively. For patients with im-
used to assess bone turnover in dialyzed patients. Al-paired renal function, dosages should be reduced to 500
though these levels have been found to be more sensitivemg and 300 mg b.i.d.
than the previously employed radioimmunoassays, at
Potential complications of bone biopsies present there is no consensus regarding the serum level
of PTH that reflects normal bone turnover in ESRDComplications from bone biopsies can include pain,
patients. A recent study in our laboratory found thathematoma, wound infection, and rarely neuropathy.
However, studies show that horizontal or transiliac and serum PTH levels between 65 and 450 pg/ml, seen in the
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majority of dialysis patients, are not predictive of the to assess in different laboratories, and low levels of RNA
gene expression may escape detection if the correspond-underlying bone disease [7]. Because bone biopsies pro-
vide a sensitive measurement of bone changes, they more ing autoradiographic signal is dispersed over a large sur-
face of the section or is masked by background. There-accurately determine the type of renal osteodystrophy
and can indicate potential aluminum accumulation in fore, caution must be used before important biological
conclusions are drawn from negative results. Finally,dialyzed patients [8]. Bone biopsies also allow tailored
therapeutic measures. The extent of aluminum deposits specificity relies on the choice of suitable sequences of
probe and stringency adopted for the hybridization pro-at the bone–osteoid interface and the level of bone turn-
over determine the optimal duration of chelation therapy. cedure. Moreover, ISHH reveals only intracellular RNA
transcripts and does not provide information about theIf the biopsy shows no significant deposits of alumi-
num, the degree of bone turnover will help the prac- subsequent steps of protein synthesis and extracellular
secretion unless associated with immunohistochemistry.titioner determine the route, aggressiveness, and length
of calcitriol therapy. Severe hyperparathyroidism with
Immunohistochemistrymarked bone marrow fibrosis is an indication for high
doses of intravenous calcitriol if the calcium phosphorus IHC is highly complementary to ISHH in that it links
the transcriptional and translational mechanisms of cells.product can be controlled. A bone biopsy can predict
whether there will be high resistance to intravenous IHC assesses the metabolic state of bone cells by visualiz-
ing protein production. Although the technique of IHCcalcitriol at the needed massive doses. In this case, para-
thyroidectomy may be necessary. The severity of the is well established in soft tissue, its use with hard tissue
such as bone is relatively new. Therefore, researcherseffect of secondary hyperparathyroidism on bone may
also indicate the extent of the post-parathyroidectomy using IHC must be particularly careful to ensure a reli-
able and reproducible outcome.“hungry bone syndrome” and allow preventive measures
such as the preoperative injection of calcitriol. In patients
Information derived from molecular histologywith mild to moderate increase in bone turnover with
Researchers have demonstrated that factors believedor without mineralization defect, doses of intravenous
to play important roles in regulating bone turnover areor preoperative calcitriol and duration of therapy may
expressed in bone cells. ISHH has documented expres-be adjusted to avoid the development of ABD. In case
sion of bone matrix proteins, including type I collagen,of ABD, calcitriol therapy is not desirable because of
osteocalcin, and osteopontin. These proteins are associ-the risk of inducing hypercalcemia and extraosseous cal-
ated with cell-to-cell and cell-to-mineralized matrix ad-cifications.
hesion. ISHH has also documented changes in biologicalA bone biopsy establishes the precise relationships
activity measured by type I collagen and osteopontinbetween serum indices of calcium metabolism and bone
mRNA expression in bone cells. The vitamin D receptor,lesions. This enhances the interpretation of longitudinal
which plays an important role in regulating bone turn-follow-up of noninvasive parameters while the patient
over, has been shown to be expressed in bone cellsis undergoing a particular therapy.
through ISHH.
Recently, we used histomorphometric and ISHH tech-
MOLECULAR BONE HISTOLOGY
niques to document expressions of the cytokine interleu-
In situ hybridization histochemistry (ISHH) and im- kin-6 (IL-6) and its receptor IL-6R in renal osteodystro-
munohistochemistry (IHC) are two powerful methodol- phy patients. IL-6 is believed to be a significant factor
ogies used to investigate bone cell metabolism. in bone remodeling. Our findings indicate that IL-6 and
IL-6R are intricately involved in osteoclastic bone re-
In situ hybridization histochemistry
sorption [9].
Using complementary RNA probes labeled with a re- Although molecular histology is still in its beginnings,
porter molecule, ISHH can detect cellular nucleic acids, its value has been clearly established. The continuing
and therefore reveals cellular sources and differential development of more efficient, economical methods will
gene expressions of specific biomolecules involved in lead to its routine use as a morphological tool in the
bone metabolism, i.e., cytokines, matrix proteins, and study of bone.
receptor species. When applied to undecalcified bone
section, ISHH can evaluate the relationship between
CONCLUSIONSgene expression and cell number and activity in the bone
microenvironment. Bone biopsies are presently much more widely used
for diagnosis and research than they have been in theDespite the invaluable information it provides, ISHH
also has several limits that must be kept in mind when past. However, traditional constraints continue to be per-
ceived because of the procedure’s invasiveness and cost,interpreting results. The sensitivity of ISHH is difficult
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